This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0422U only for Guardant360Response™ from Guardant Health Inc. To evaluate patient response to anticancer therapy, the test uses a next–generation sequencing (NGS) targeted sequence analysis panel to evaluate cell–free circulating DNA from a blood specimen for genes associated with solid–organ neoplasms. Using an algorithm to compare the results with those from an earlier, baseline test (0326U), 0422U reports a quantitative change from baseline, including specific alterations, if present.
For clinical responsibility, terminology, tips and additional info
start codify free trial.